Drug Combination Details
| General Information of the Combination (ID: C75724) | |||||
|---|---|---|---|---|---|
| Name | Schisandrol B NP Info | + | Docetaxel Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Ca Ski | CVCL_1100 | Cervical squamous cell carcinoma | Homo sapiens | ||
| In-vivo Model | Mice were subcutaneously implanted with cell suspension holding 1*106 Caski cells in the right flank. | |||||
| Experimental
Result(s) |
Sch B enhanced the anti-tumor effects of DTX in vitro and in vivo via growth, invasion, and apoptosis regulating. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Schisandrin B synergizes docetaxel-induced restriction of growth and invasion of cervical cancer cells in vitro and in vivo. Ann Transl Med. 2020 Sep;8(18):1157. | |||
